ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Summary

This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.

Timeline

Start

2014-04

Primary completion

2016-03

Completion

2017-09

Drugs

Indications